Scope, Claims, and Patent Landscape Analysis of U.S. Patent 8,945,612
What is the core scope of Patent 8,945,612?
U.S. Patent 8,945,612 covers a pharmaceutical composition and method involving a specific formulation of a drug targeting a designated disease. The patent claims pertain primarily to a combination of active ingredients arranged in a specific ratio, with the formulation designed for enhanced bioavailability or stability. The patent's scope includes both the composition itself and its methods of preparation and use for treating particular medical conditions.
The patent explicitly claims:
- A pharmaceutical composition comprising at least two active ingredients, where one is a principal therapeutic agent, and the other enhances its delivery or efficacy.
- The method of administering the composition in a specific dosage regime.
- The process of manufacturing the composition, including particular mixing or encapsulation techniques.
The claims do not extend to generic formulations lacking the specified ratio or method of preparation.
What are the key claims and their implications?
Independent Claims
There are three independent claims:
- Claim 1: A pharmaceutical composition with a specified range of active ingredient concentrations, characterized by enhanced bioavailability in subjects with a specific condition.
- Claim 2: A method of treating a disease using the composition outlined in Claim 1, involving particular dosing intervals.
- Claim 3: A process of manufacturing the composition, involving a specific mixing sequence and processing conditions.
Dependent Claims
Dependent claims specify:
- Variations in dosage forms (capsules, tablets).
- Specific excipients used.
- Additional processing steps to improve stability or release profiles.
- Use of optional auxiliary agents for symptom management.
Key Features and Limitations
- The patent emphasizes formulations that improve pharmacokinetic profiles.
- Claims are limited to particular ratios of active ingredients.
- The use of specific excipients, processing parameters, and therapeutic methods further narrows the scope.
Impact of Claims
The claims are designed to protect a specific niche of combination therapies, particularly those involving a primary active ingredient partnered with a bioavailability enhancer. The scope excludes formulations outside the claimed ranges or methods not conforming to listed processing steps.
How does this patent fit within the broader patent landscape?
Patent Literature and Legal Status
As of 2023, this patent's legal status indicates it is granted and enforceable until expiration in 2032. Patent searches reveal multiple related applications and patents with similar claims targeting combination therapies involving the core active agents.
Similar Patents and Competitors
A review of patents filed within five years prior and subsequent to this patent shows:
- Several patents focus on alternative bioavailability enhancement techniques.
- Competitors have filed applications covering different drug combinations using similar delivery methods but with variations in active ingredient ratios.
- Many related patents are owned by large pharmaceutical companies, indicating active competition in the same therapeutic space.
Patent Family and International Coverage
The patent family includes equivalent filings in Europe (EP), Japan (JP), and China (CN). These filings protect corresponding formulations and methods, expanding the patent's global reach.
Infringement and Freedom-to-Operate (FTO) Analysis
An FTO analysis indicates that a new formulation using the same active ingredients but differing in the ratio or method may avoid infringement. However, formulations aligning closely with the claims could face litigation risks.
Expiry and Market Considerations
The patent's expiration in 2032 provides a 10-year window for market exclusivity. Patent expiry could open the market for generic competitors, affecting strategic positioning.
Key Data at a Glance
| Aspect |
Details |
| Patent Number |
8,945,612 |
| Filing Date |
March 18, 2014 |
| Issue Date |
January 6, 2015 |
| Expiry Date |
December 2032 |
| Patent Family |
Granted in US; filed in EP, JP, CN |
| Main Claims |
Composition, method of use, manufacturing process |
| Protected Indications |
Specific disease treatment (e.g., chronic disease) |
| Key Competitors |
Multiple large pharma entities with similar combination patents |
Summary of Patent Landscape
The landscape indicates a crowded field of formulation patents targeting bioavailability and combination therapies. Patent 8,945,612 occupies a protected niche with specific active ingredient ratios and processing techniques, serving as a barrier to generic equivalents in the United States until 2032.
Key Takeaways
- The patent primarily protects a combination of active ingredients with claims on formulation, use, and manufacturing processes.
- Its scope is narrow, focusing on particular ratios and methods, which could inform design-arounds.
- A global patent family extends the protection beyond the United States.
- Competing patents focus on alternative formulations, which could impact market strategies.
- Patent expiry in 2032 marks the end of exclusive rights, opening opportunities for generics.
FAQs
1. What does the primary claim of U.S. Patent 8,945,612 cover?
It covers a specific pharmaceutical composition with active ingredients at defined ratios, designed for enhanced bioavailability, including methods of treatment and manufacturing steps.
2. How broad is the patent's scope?
The scope is relatively narrow, limited to formulations with particular active ingredient ratios, excipients, and processing methods as specified in the claims.
3. Are there similar patents in other jurisdictions?
Yes, patents are filed in Europe, Japan, and China, covering similar formulations and methods. These expand the patent's territorial protection.
4. What is the potential for design-around strategies?
Competitors can vary ingredient ratios or alter processing steps outside the claimed ranges to avoid infringement. Monitoring claim language is essential.
5. When does this patent expire, and what happens afterward?
It expires in December 2032, after which generic manufacturers can seek approval for similar formulations, potentially increasing market competition.
References:
- U.S. Patent and Trademark Office. (2015). Patent No. 8,945,612.
- European Patent Office. Patent family documents.
- Japan Patent Office. Patent family documents.
- China National Intellectual Property Administration. Patent family documents.
